Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
<h4>Introduction</h4> <p>Many analgesics have been withdrawn from the market because of adverse drug reactions. Controversy still surrounds the use of some approved analgesics for pain management. However, the trends and reasons for withdrawal of analgesics when harms are attribut...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Taylor and Francis
2017
|
| _version_ | 1797050754465267712 |
|---|---|
| author | Onakpoya, I Heneghan, C Aronson, J |
| author_facet | Onakpoya, I Heneghan, C Aronson, J |
| author_sort | Onakpoya, I |
| collection | OXFORD |
| description | <h4>Introduction</h4> <p>Many analgesics have been withdrawn from the market because of adverse drug reactions. Controversy still surrounds the use of some approved analgesics for pain management. However, the trends and reasons for withdrawal of analgesics when harms are attributed to their use have not been systematically assessed.</p> <h4>Areas covered</h4> <p>We conducted searches in PubMed; Embase; Google Scholar; clinicaltrials.gov; WHO databases of withdrawn products; websites of the European Medicines Agency, the US Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency; Meyler’s Side Effects of Drugs; Stephens’ Detection of New Adverse Drug Reactions; the Pharmaceutical Manufacturing Encyclopedia; and the Merck Index. We included licensed analgesics that were withdrawn after marketing because of adverse reactions between 1950 and March 2017. We excluded herbal products, non-human medicines, and non-prescription medicines. We used the Oxford Centre for Evidence Based Medicine criteria to document the levels of evidence, and chi-squared tests to compare withdrawal patterns across geographical regions.</p> <h4>Expert opinion</h4> <p>Pharmacovigilance systems in low-resource settings should be strengthened. Greater co-ordination across regulatory authorities in assessing and interpreting the benefit-harm balance of new analgesics should be encouraged. Future reporting of harms in clinical trials of analgesics should follow standardized guidelines.</p> |
| first_indexed | 2024-03-06T18:09:52Z |
| format | Journal article |
| id | oxford-uuid:02a4949a-2855-4608-bcff-a63595c80fd2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:09:52Z |
| publishDate | 2017 |
| publisher | Taylor and Francis |
| record_format | dspace |
| spelling | oxford-uuid:02a4949a-2855-4608-bcff-a63595c80fd22022-03-26T08:41:54ZPost-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic reviewJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:02a4949a-2855-4608-bcff-a63595c80fd2EnglishSymplectic Elements at OxfordTaylor and Francis2017Onakpoya, IHeneghan, CAronson, J <h4>Introduction</h4> <p>Many analgesics have been withdrawn from the market because of adverse drug reactions. Controversy still surrounds the use of some approved analgesics for pain management. However, the trends and reasons for withdrawal of analgesics when harms are attributed to their use have not been systematically assessed.</p> <h4>Areas covered</h4> <p>We conducted searches in PubMed; Embase; Google Scholar; clinicaltrials.gov; WHO databases of withdrawn products; websites of the European Medicines Agency, the US Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency; Meyler’s Side Effects of Drugs; Stephens’ Detection of New Adverse Drug Reactions; the Pharmaceutical Manufacturing Encyclopedia; and the Merck Index. We included licensed analgesics that were withdrawn after marketing because of adverse reactions between 1950 and March 2017. We excluded herbal products, non-human medicines, and non-prescription medicines. We used the Oxford Centre for Evidence Based Medicine criteria to document the levels of evidence, and chi-squared tests to compare withdrawal patterns across geographical regions.</p> <h4>Expert opinion</h4> <p>Pharmacovigilance systems in low-resource settings should be strengthened. Greater co-ordination across regulatory authorities in assessing and interpreting the benefit-harm balance of new analgesics should be encouraged. Future reporting of harms in clinical trials of analgesics should follow standardized guidelines.</p> |
| spellingShingle | Onakpoya, I Heneghan, C Aronson, J Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review |
| title | Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review |
| title_full | Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review |
| title_fullStr | Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review |
| title_full_unstemmed | Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review |
| title_short | Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review |
| title_sort | post marketing withdrawal of analgesic medications because of adverse drug reactions a systematic review |
| work_keys_str_mv | AT onakpoyai postmarketingwithdrawalofanalgesicmedicationsbecauseofadversedrugreactionsasystematicreview AT heneghanc postmarketingwithdrawalofanalgesicmedicationsbecauseofadversedrugreactionsasystematicreview AT aronsonj postmarketingwithdrawalofanalgesicmedicationsbecauseofadversedrugreactionsasystematicreview |